Document:

Exhibit 10.1

 

Christopher Gruseke Employment Agreement

 

This Employment Agreement (the “Agreement”) is made and entered into as of February 25, 2015, by and among Christopher Gruseke (the “Executive”) on the one side, and Bankwell Financial Group, Inc. a Connecticut bank holding company (the “Company”) and its wholly-owned bank subsidiary, Bankwell Bank (the “Bank”).  Unless a distinction is appropriate, the term “Company” in this Agreement shall include the Bank.

 

WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and

 

WHEREAS, the Executive desires to be employed by the Company on such terms and conditions.

 

NOW, THEREFORE, in consideration of the mutual covenants, promises and obligations set forth herein, the parties agree as follows:

 

1.     Term. The Executive’s employment hereunder shall be effective as of February 25, 2015 (the “Effective Date”) and shall continue until January 5, 2019, unless terminated earlier pursuant to Section 5 of this Agreement. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as the “Employment Term.”

 

2.     Position and Duties.

 

2.1      Position. During the Employment Term the Executive shall serve as President and Chief Executive Officer of the Company and Chief Executive Officer of the Bank and shall report to the Board of Directors of the Company and the Bank. In such positions, the Executive shall have such duties, authority and responsibility as shall be determined from time to time by the Board of Directors of the Company and the Bank, which duties, authority and responsibility are consistent with the Executive’s position. The Executive shall be nominated to serve on the Board of Directors of the Company during the Employment Term and shall be appointed to and shall serve on the Board of Directors of the Bank, in all cases in an uncompensated capacity. In addition, if requested, the Executive will also serve as an officer or director of any other affiliate of the Company for no additional compensation.

 

    	1

    	 

    
 

 

2.2      Duties. During the Employment Term, the Executive shall devote substantially all of his business time and attention (other than during weekends, holidays, vacation periods, and periods of illness or leaves of absence) to the performance of the Executive’s duties hereunder and will not engage in any other business, profession or occupation for compensation or otherwise which would conflict or interfere with the performance of such services either directly or indirectly  without the prior written consent of the Board. Notwithstanding the foregoing, the Executive will be permitted to:

 

(a) with the prior written consent of the Company’s Chairman of the Compensation Committee  act or serve as a director, trustee, committee member or advisor of any type of business, civic or charitable organization, and

 

(b) purchase or own less than five percent (5%) of the securities or ownership interests of any corporation, partnership or limited liability company; provided that, such ownership represents a passive investment and that the Executive is not a controlling person of, or a member of a group that controls, such corporation, partnership or limited liability company; provided further that, the activities described in clauses (a) and (b) do not interfere with the performance of the Executive’s duties and responsibilities to the Company as provided hereunder.

 

3.     Place of Performance. The principal place of the Executive’s employment shall be the Company’s executive office currently located in New Canaan, Connecticut; provided that, the Executive will be required to travel on Company business during the Employment Term. The Company shall provide the executive at his principal place of employment with a private office, secretarial services and other support services and facilities suitable to his position with the Company and the Bank and necessary or appropriate in connection with the performance of his assigned duties under this Agreement.

 

4.     Compensation.

 

4.1      Base Salary. The Company shall pay the Executive an annual rate of base salary of $450,000 in periodic instalments in accordance with the Company’s customary payroll practices, but no less frequently than monthly.  The Executive’s annual base salary may be increased from time to time by the Board of Directors or a committee thereof, but may not be decreased without the Executive’s written consent.  The Executive’s annual base salary, as in effect from time to time, is hereinafter referred to as “Base Salary”.

 

4.2      Annual Bonus.  The Executive will be included in the Company’s Executive Incentive Plan (“EIP”) for the years 2015 and beyond (the “Annual Bonus”).  The EIP currently has a target opportunity of 35% of base salary for the CEO.  The Compensation Committee will determine the final form of the EIP and awards under it, but currently expects to review the EIP for appropriate revisions with consideration given, as applicable, to asset growth, successful capital management, merger and acquisition accomplishments and the like. The target and maximum incentive opportunities for the Executive and others in the EIP will be reviewed and adjusted based on consultant recommendations, input from the Executive and final review and determination by the Compensation Committee.

 

4.3      Signing Stock Award. In consideration of the Executive entering into this Agreement and as an inducement to join the Company, on February 25, 2015, the Company will grant the following equity award to the Executive pursuant to the Company’s current equity plans: 40,000 restricted shares of Company common stock, with 25% (10,000 shares) vesting on December 31 of each of 2015, 2016, 2017 and 2018. The form of the stock award is attached hereto and incorporated herein as Exhibit A.

    	2

    	 

    
 

 

4.4      Fringe Benefits and Perquisites. During the Employment Term, the Executive shall be entitled to fringe benefits and perquisites consistent with the practices of the Company, and to the extent the Company provides similar benefits or perquisites (or both) to similarly situated executives of the Company.

 

4.5      Employee Benefits. During the Employment Term, the Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company, as in effect from time to time (collectively, “Employee Benefit Plans”), on a basis which is no less favorable than is provided to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee Benefit Plans. The Company reserves the right to amend or cancel any Employee Benefit Plan at any time in its sole discretion, subject to the terms of such Employee Benefit Plan and applicable law.

 

4.6      Vacation. During the Employment Term, the Executive shall be entitled to twenty (20) paid vacation days per calendar year (pro-rated for partial years) in accordance with the Company’s vacation policies, as in effect from time to time.

 

4.7      Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the Executive in connection with the performance of the Executive’s duties hereunder in accordance with an expense reimbursement policy and procedures approved by the Compensation Committee and the Chief Financial Officer.

 

4.8       Indemnification.

 

(a)           In the event that the Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), other than any Proceeding initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company or any of its affiliates with respect to this Agreement or the Executive’s employment hereunder, by reason of the fact that the Executive is or was a director or officer of the Company, or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, employee or agent of another corporation or a partnership, joint venture, trust or other enterprise, the Executive shall be indemnified and held harmless by the Company to the fullest extent permitted by applicable law from and against any liabilities, costs, claims and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys’ fees). Executive shall be provided with an Indemnification Agreement in the form used for other executives of the Company.

 

(b)           During the Employment Term and for a period of six (6) years thereafter, the Company or any successor to the Company shall purchase and maintain, at its own expense, directors’ and officers’ liability insurance providing coverage to the Executive on terms that are no less favorable than the coverage provided to other directors and senior officers of the Company.

 

    	3

    	 

    
 

 

4.9      Clawback Provisions. Notwithstanding any other provision in this Agreement to the contrary, any incentive-based compensation, or any other compensation, paid to the Executive pursuant to this Agreement or any other agreement or arrangement with the Company which is  subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).

 

4.10   Required Regulatory Provisions.  Notwithstanding anything herein contained to the contrary, any payments to the Executive by the Company, whether pursuant to this Agreement or otherwise, are subject to and conditioned upon their compliance with Section 18(k) of the Federal Deposit Insurance Act, 12 U.S.C. Section 1828(k), and the regulations promulgated thereunder in 12 C.F.R. Part 359.

 

5.     Termination of Employment. Upon termination of the Executive’s employment during the Employment Term, the Executive shall be entitled to the compensation and benefits described in this Section 5 and shall have no further rights to any compensation or any other benefits from the Company, the Bank or any of their affiliates.

 

5.1      Expiration of the Term, for Cause or Without Good Reason.

 

(a)        The Executive’s employment hereunder may be terminated upon the expiration of the Employment Term without renewal by either party or during the Employment Term by the Company for Cause or by the Executive without Good Reason. If the Executive’s employment is so terminated, the Executive shall be entitled to receive:

 

	
  

	
(i)

	
any accrued but unpaid Base Salary and accrued but unused vacation pay which shall be paid on the pay date immediately following the Termination Date (as defined in Section 5.6 below) in accordance with the Company’s customary payroll procedures;

 

	
  

	
(ii)

	
any earned but unpaid Annual Bonus with respect to any completed calendar year immediately preceding the Termination Date, which shall be paid on the otherwise applicable payment date, except to the extent payment is otherwise deferred pursuant to any applicable deferred compensation arrangement;

 

	
  

	
(iii)

	
reimbursement for unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company’s expense reimbursement policy; and

 

	
  

	

(iv)

	

such employee benefits (including equity compensation), if any, as to which the Executive may be entitled under the Company’s employee benefit plans or Equity Awards as of the Termination Date; provided that, in no event shall the Executive be entitled to any payments in the nature of severance or termination payments except as specifically provided herein.

 

Items 5.1(a)(i) through 5.1(a)(iv) are referred to herein collectively as the “Accrued Amounts”.

 

    	4

    	 

    
 

 

(b)        For purposes of this Agreement, “Cause” shall mean:

 

	
  

	
(i)

	

the Executive’s conviction of any crime involving fraud, embezzlement, theft or dishonesty, moral turpitude or any similar issue that in the reasonable opinion of the Board of Directors of the Company would materially and negatively impact the reputation of the Company, the Bank or any of their affiliates or the Executive’s ability to perform his duties;

 

	
  

	
(ii)

	

serious wilful misconduct by the Executive, including a material violation of the Company’s Code of Conduct or the Executive’s material personal dishonesty in connection with the business or customers of the Company or the material breach of fiduciary duty to the Company, the Bank or their customers for personal profit;

 

	
  

	
(iii)

	

any material breach by the Executive of any material provision of  this Agreement;

 

	
  

	

(iv)

	

any wilful failure by the Executive to follow a reasonable and lawful directive of the Boards of Directors of the Company as described in Section 2.1(b) above, other than any failure resulting from the Executive’s incapacity due to physical or mental injury or illness;

 

	
  

	

(v)

	

any wilful failure to keep confidential information of the Company, Bank or their affiliates confidential (except as necessary to the performance of his duties in his reasonable discretion);

 

	
  

	

(vi)

	

the failure of the Executive, in the opinion of 100% of the full membership of the Board of Directors of the Company excluding the Executive, to perform his duties as described herein;

 

	
  

	

(vii)

	

the Executive’s arrest for any crime involving fraud, embezzlement, theft or dishonesty that in the sole opinion of two-thirds or more of the full membership of the Board of Directors of the Company excluding the Executive would negatively impact the reputation of the Company or  the Bank or the Executive’s ability to perform his duties; or

 

	
  

	

(viii)

	

if the regulatory authorities of the Company or the Bank issue an order removing the Executive from his positions at the Company or the Bank, or if such regulatory authorities inform the Board of Directors that the continuation of the Executive in his officer positions at the Company or the Bank would constitute an unsafe and unsound banking practice.

 

The Company cannot terminate Executive’s employment for Cause unless he has been provided written notice from the Company of the existence of the circumstances providing grounds for termination for Cause. If the Cause circumstances are capable of being cured, Executive shall have up to thirty (30) days (up to 90 days in the event of a wrongful arrest) from the date on which such notice is provided to cure such circumstances. If the Executive remedies the condition within such cure period, then no Cause shall be deemed to exist with respect to such condition. If the Executive does not  remedy the condition within the cure period, or if he fails to diligently pursue cure in good faith during the cure period, then the Company may deliver a notice of termination for Cause at any time.

    	5

    	 

    
 

 

In the event that the Executive is terminated for Cause based on Section 5.1(b)(i) or (vii) above and, after the case is fully adjudicated (including all appeals), the Executive is subsequently found innocent of these charges on the merits of the case by any court of competent jurisdiction or the appropriate administrative agency, then the Executive will be entitled to receive at that time the amounts payable due to a termination without Cause.  Such amounts will be paid no later than the end of the calendar year in which the Executive is fully adjudicated to be innocent of the charges.

 

(c)           For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following, in each case during the Employment Term without the Executive’s written consent:

 

	
  

	
(i)

	

a material reduction in the Executive’s Base Salary;

 

	
  

	
(ii)

	

a material reduction in the Executive’s EIP target bonus opportunity;

 

	
  

	
(iii)

	

a relocation of the Executive’s principal place of employment by more than fifty miles;

 

	
  

	

(iv)

	

any material breach by the Company of any material provision of this Agreement;

 

	
  

	

(v)

	

the Company’s failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law;

 

	
  

	

(vi)

	

the Company’s failure to nominate the Executive for election to the Board of the Company and the Bank and to use its best efforts to have his elected and re-elected, as applicable;

 

	
  

	

(vii)

	

a material, adverse change in the Executive’s title, authority, duties or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law).  This provision shall not apply in the context of a Change in Control, as defined in Section 5.4(b) below, if:

 

	
  

	

(A)

	

an agreement which (i) is binding on the Company or its successor and on the Executive and (ii) is entered into substantially concurrently with the date the Company first agrees to the Change in Control, provided that the Executive will become the Chief Executive Officer of the Company or its successor reporting  directly to the Company or its successor’s Board of Directors no later than 12 months following the Change in Control;

 

    	6

    	 

    
 

 

	
  

	

(B)

	

the Executive’s employment continues under the terms of this Agreement or modified terms that are no less favourable to the Executive than the terms of this Agreement;

 

	
  

	

(C)

	

during the period between the Change in Control and assumption of the position as Chief Executive Officer, the Executive is the second highest ranked executive officer of the Company or its successor with responsibilities and perquisites as are appropriate to that position; and

 

	
  

	

(D)

	

from the date of the Change in Control, the Executive remains a member of or is appointed to the Board of Directors of the Company or its successor; or

 

	
  

	

(viii)

	

a material adverse change in the reporting structure applicable to the Executive, including any requirement that the Executive report to a corporate officer or employee of the Company or the Bank instead of reporting directly to the Board of Directors of the Company and the Bank.

 

The Executive cannot terminate his employment for Good Reason unless he has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within thirty (30) days of the initial existence of such grounds and the Company has had thirty (30) days from the date on which such notice is provided to cure such circumstances. If the Company remedies the condition within such thirty (30) day cure period, then no Good Reason shall be deemed to exist with respect to such condition. If the Company does not remedy the condition within such thirty (30) day cure period, then the Executive may deliver a notice of termination for Good Reason at any time within sixty (60) days following the expiration of such cure period. If the Executive does not terminate his employment for Good Reason within sixty (60) days following the expiration of the cure period, then the Executive will be deemed to have waived his right to terminate for Good Reason with respect to such grounds.

 

5.2      Without Cause or for Good Reason. The Employment Term and the Executive’s employment hereunder may be terminated by the Executive for Good Reason or by the Company without Cause. In the event of such termination (unless Section 5.4 below is applicable), the Executive shall be entitled to receive the Accrued Amounts and, subject to the Executive’s compliance with Section 6, Section 7 and Section 8 of this Agreement and his execution of a mutually agreeable release of claims in favor of the Company, the Bank and their affiliates and their respective officers and directors (a “Release”) and such Release becoming effective as provided therein (“Release Execution Period”), the Executive shall be entitled to receive the following:

 

(a)           A lump sum payment equal to the sum of the Executive’s then current Base Salary and the Annual Bonus earned for the calendar year prior to the calendar year in which the Termination Date occurs, multiplied by two. The payment shall be made within ten (10) business days following the expiration of the Release Execution Period.

    	7

    	 

    
 

 

(b)           If the Executive timely and properly elects continuation coverage under the Consolidated Omnibus Reconciliation Act of 1985 (“COBRA”), the Company shall reimburse the Executive for the difference between the monthly COBRA premium paid by the Executive for himself and his dependents and the monthly premium amount paid by similarly situated active executives. Such reimbursement shall be paid to the Executive on or before the fifteenth (15th) day of the month immediately following the month in which the Executive timely remits the premium payment. The Executive shall be eligible to receive such reimbursement until the earliest of: (i) the expiration of the Severance Period; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive receives/becomes eligible to receive substantially similar coverage from another employer.

 

(c)           The treatment of any outstanding Equity Awards shall be determined in accordance with the terms of the relevant equity plan(s) as contemplated in Sections 4.3 and 4.4 above and the applicable award agreements.

 

	
  

	
5.3

	
Death or Disability.

 

(a)           The Executive’s employment hereunder shall terminate automatically upon the Executive’s death during the Employment Term, and the Company may terminate the Executive’s employment on account of the Executive’s Disability.

 

(b)           If the Executive’s employment is terminated during the Employment Term on account of the Executive’s death or Disability, the Executive (or the Executive’s estate and/or beneficiaries, as the case may be) shall be entitled to receive the following:

 

	
  

	
(i)

	

the Accrued Amounts; and

 

	
  

	
(ii)

	

a lump sum payment equal to the pro-rata Annual Bonus, if any, that the Executive would have earned for the EIP year in which the Termination Date occurs based on the achievement of applicable performance goals for such year, which shall be payable on the date that annual bonuses are paid to the Company’s similarly situated executives, but in no event later than two-and-a-half (2 1/2) months following the end of the calendar year in which the Termination Date occurs.

 

(c)           For purposes of this Agreement, Disability shall mean that the Executive is entitled to receive long-term disability benefits under the Company’s long-term disability plan, or if there is no such plan, the Executive’s inability, due to physical or mental incapacity, to substantially perform his essential duties and responsibilities under this Agreement for ninety (90) days out of any three hundred sixty-five (365) day period; provided however, in the event the Company temporarily replaces the Executive, or transfers the Executive’s duties or responsibilities to another individual on account of the Executive’s inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive’s employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof.

    	8

    	 

    
 

 

Any question as to the existence of the Executive’s Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.

 

	
  

	
5.4

	
Change in Control Termination.

 

(a)        Notwithstanding any other provision contained herein, if the Executive’s employment hereunder is terminated by the Executive for Good Reason or by the Company without Cause (other than on account of the Executive’s death or Disability), in each case either concurrently with or within twenty-four (24) months following a Change in Control, the Executive shall be entitled to receive the Accrued Amounts and, subject to the Executive’s compliance with Section 6, Section 7 and Section 8 of this Agreement and his execution of a Release which becomes effective as provided therein, for which the Company assigns significant value in agreeing to this Section 5.4,  the Executive shall be entitled to receive the following:

 

	
  

	
(i)

	

a lump sum payment upon the effectiveness of the Release equal to three (3) times his average base salary and annual cash incentive payments (partial years being annualized) for the immediately preceding five (5) taxable years (or such shorter period as the Executive was employed);

 

	
  

	
(ii)

	

If the Executive timely and properly elects continuation coverage under COBRA, the Company shall reimburse the Executive for the difference between the monthly COBRA premium paid by the Executive for himself and his dependents and the monthly premium amount paid by similarly situated active executives. Such reimbursement shall be paid to the Executive on the fifteenth (15th) day of the month immediately following the month in which the Executive timely remits the premium payment. The Executive shall be eligible to receive such reimbursement until the earliest of:

 

(x)     the second year anniversary of the Termination Date;

 

(y)     the date the Executive is no longer eligible to receive COBRA continuation coverage; and

 

(z)     the date on which the Executive receives/becomes eligible to receive substantially similar coverage from another employer.

    	9

    	 

    
 

 

(b)           The term “Change in Control” shall mean the occurrence of any one or more of the following:

 

	
  

	
(i)

	

one person (or more than one person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group, constitutes more than fifty percent (50% of the total fair market value or total voting power of the stock of the Company; provided that, a Change in Control shall not occur if any person (or more than one person acting as a group) owns more than fifty percent (50%)  of the total fair market value or total voting power of the Company’s stock and acquires additional stock;

	
  

	
(ii)

	

one person (or more than one person acting as a group) acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) ownership of the Company’s stock possessing thirty percent (30%) or more of the total voting power of the stock of the Company;

	
  

	

(iii)

	

a majority of the members of the Board of Directors of the Company are replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the Board before the date of appointment or election; or

	
  

	

(iv)

	

the sale of all or substantially all of the Company’s assets defined as the acquisition of Company assets having a fair market value, without regard to liabilities of 40% or more of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition.

 

For purposes of this Agreement, the terms “person” and “acting as a group” shall have the meanings specified in the Code and the regulations thereunder.  In no event, however, shall a Change in Control be deemed to have occurred as a result of any acquisition of securities or assets of the Company, the Bank, or a subsidiary of either of them, by the Company, the Bank, or any subsidiary of either of them, or by any employee benefit plan maintained by any of them.  Notwithstanding the foregoing, a Change in Control shall not occur unless such transaction constitutes a change in the ownership of the Company or the Bank, a change in the effective control of the Company or the Bank or a change in the ownership of a substantial portion of the assets of the Company or the Bank, in each case as provided under Section 409A of the Code and the regulations thereunder.

 

5.5   Notice of Termination. Any termination of the Executive’s employment hereunder by the Company or by the Executive during the Employment Term (other than termination pursuant to Section 5.3(a) on account of the Executive’s death) shall be communicated by a written notice of termination (“Notice of Termination”) to the other party hereto in accordance with Section 22. The Notice of Termination shall specify:

 

    	10

    	 

    
 

 

(a)           the termination provision of this Agreement relied upon;

 

(b)           to the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated; and

 

(c)           the applicable Termination Date.

 

5.6   Termination Date. The Executive’s Termination Date shall be:

 

(a)           If the Executive’s employment hereunder terminates on account of the Executive’s death, the date of the Executive’s death;

 

(b)           If the Executive’s employment hereunder is terminated on account of the Executive’s Disability, the date that it is determined that the Executive has a Disability;

 

(c)           If the Company terminates the Executive’s employment hereunder for Cause, the date the Notice of Termination is delivered to the Executive;

 

(d)           If the Company terminates the Executive’s employment hereunder without Cause, the date specified in the Notice of Termination, which shall be no less than thirty (30) days following the date on which the Notice of Termination is delivered; provided that, the Company shall have the option to provide the Executive with a lump sum payment equal to thirty (30) days’ Base Salary in lieu of such notice, which shall be paid in a lump sum on the Executive’s Termination Date and for all purposes of this Agreement, the Executive’s Termination Date shall be the date on which such Notice of Termination is delivered; and

 

(e)           If the Executive terminates his employment hereunder with or without Good Reason, the date specified in the Executive’s Notice of Termination, which shall be no less than thirty (30) days following the date on which the Notice of Termination is delivered; provided that, the Company may waive all or any part of the thirty (30) day notice period for no consideration by giving written notice to the Executive and for all purposes of this Agreement, the Executive’s Termination Date shall be the date determined by the Company.

 

Notwithstanding anything contained herein, the Termination Date shall not occur until the date on which the Executive incurs a “separation from service” within the meaning of Section 409A.

 

5.7   Mitigation. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and except as provided with respect to COBRA reimbursements, any amounts payable pursuant to this Section 5 shall not be reduced by compensation the Executive earns on account of employment with another employer.

 

5.8   Resignation of All Other Positions. Upon termination of the Executive’s employment hereunder for any reason, the Executive agrees to resign, effective on the Termination Date and shall be deemed to have resigned from all positions that the Executive holds as an officer or  member of the board of directors (or a committee thereof) of the Company, the Bank or any of their affiliates.

    	11

    	 

    
 

 

5.9   Section 280G .

 

(a)           If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the Executive’s termination of employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement, or otherwise) (all such payments collectively referred to herein as the “280G Payments”) constitute “parachute payments” within the meaning of Section 280G of the Code and will be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then such 280G Payments shall be reduced by the minimum amount required so that no amount payable to the Executive will be subject to the Excise Tax (with the cash severance to be reduced first and with any further reductions that may be required to be determined by Tax Counsel (as defined below) in a manner that minimizes the impact to the Executive).

 

(b)           All calculations and determinations under this Section 5.9 shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the “Tax Counsel”) whose determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this Section 5.9, the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code. The Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under this Section 5.9. The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services.

 

(c)           The Executive hereby agrees with the Company and any successor thereto to in good faith consider and take steps commonly used to minimize or eliminate any “parachute payments” within the meaning of Section 280G of the Code if requested to do so by the Company or any successor thereto; provided, however, that the foregoing language shall neither require the Executive to take or not take any specific action in furtherance thereof nor contravene, limit or remove any right or privilege provided to the Executive under this Agreement.

 

6.     Cooperation. The parties agree that certain matters in which the Executive will be involved during the Employment Term may necessitate the Executive’s cooperation in the future. Accordingly, following the termination of the Executive’s employment for any reason, to the extent reasonably requested by the Board, the Executive shall cooperate with the Company in connection with matters arising out of the Executive’s service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive’s other activities. The Company shall reimburse the Executive for reasonable expenses incurred in connection with such cooperation and, to the extent that the Executive is required to spend substantial time on such matters (i.e., more than 10 hours per week), the Company shall compensate the Executive at an hourly rate based on the Executive’s Base Salary on the Termination Date.

 

    	12

    	 

    
 

7.     Confidential Information. The Executive understands and acknowledges that during the Employment Term, he will have access to and learn about Confidential Information, as defined below.

 

7.1       Confidential Information Defined.

 

(a)     Definition.

 

For purposes of this Agreement, “Confidential Information” includes, but is not limited to, all information not generally known to the public, in spoken, printed, electronic or any other form or medium, relating directly or indirectly to the Company, the Bank or their affiliates, or of any other person or entity that has entrusted information to the Company in confidence. 

 

The Executive understands and agrees that Confidential Information includes information developed by him in the course of his employment by the Company as if the Company furnished the same Confidential Information to the Executive in the first instance. Confidential Information shall not include information that is generally available to and known by the public at the time of disclosure to the Executive or later; provided that, such disclosure is through no direct or indirect fault of the Executive or person(s) acting on the Executive’s behalf. 

 

Without otherwise limiting the foregoing, the parties agree that this Agreement and the terms hereof (“Contract Information”) shall constitute Confidential Information unless and until the Company determines that it or they must or should be disclosed, in whole or in part. The Company intends to coordinate any such required or desired disclosure of Contract Information with the Executive.

 

(b)     Disclosure and Use Restrictions.

 

The Executive agrees and covenants: (i) to treat all Confidential Information as strictly confidential; (ii) not to directly or indirectly disclose, publish, communicate or make available Confidential Information, or allow it to be disclosed, published, communicated or made available, in whole or part, to any entity or person whatsoever except as needed in the performance of the Executive’s authorized employment duties to the Company; and (iii) not to access or use any Confidential Information, and not to copy any documents, records, files, media or other resources containing any Confidential Information, or remove any such documents, records, files, media or other resources from the premises or control of the Company, except as needed in the performance of the Executive’s authorized employment duties to the Company and the Bank. Nothing herein shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation or order. 

 

The Executive understands and acknowledges that his obligations under this Agreement with regard to any particular Confidential Information shall commence immediately upon the Executive first having access to such Confidential Information (whether before or after he begins employment by the Company) and shall continue during and after his employment by the Company until such time as such Confidential Information has become public knowledge other than as a result of the Executive’s breach of this Agreement or breach by those acting in concert with the Executive or on the Executive’s behalf. Nothing herein shall prevent the Executive from disclosing Contract Information to his personal attorneys, accountants and other advisors, as necessary for the performance of their duties and on a confidential basis.

 

    	13

    	 

    
 

 

8.     Restrictive Covenants.

 

8.1      Acknowledgment. The Executive understands that the nature of the Executive’s position gives him access to and knowledge of Confidential Information and places him in a position of trust and confidence with the Company. The Executive understands and acknowledges that the intellectual services he provides to the Company are unique, special or extraordinary.

 

The Executive further understands and acknowledges that the Company’s ability to reserve these services for the exclusive knowledge and use of the Company is of great competitive importance and commercial value to the Company, and that improper use or disclosure by the Executive is likely to result in unfair or unlawful competitive activity.

 

8.2      Non-competition. Because of the Company’s legitimate business interest as described herein and the good and valuable consideration offered to the Executive, during the Employment Term and for the term of one (1) year, beginning on the last day of the Executive’s employment with the Company, for any reason or no reason and whether employment is terminated at the option of the Executive or the Company, the Executive agrees and covenants not to engage in Prohibited Activity within any county in which the Company, the Bank or any of their affiliates maintains as of the Termination Date or has pending as of the Termination Date a filing for permission to establish a branch, loan production office, or mortgage production office (the “Restricted Area”).

 

For purposes of this Section 8.2:

 

(a)    “Prohibited Activity” is activity in which the Executive, directly or indirectly, solely or jointly with any person or persons, as an employee, consultant, or advisor (whether or not engaged in business for profit), or as an individual proprietor, partner, shareholder, director, officer, joint venturer, investor or lender, or in any other capacity: (i) becomes affiliated with any bank or commercial lender headquartered or with branches in Fairfield or New Haven County, Connecticut; or (ii) becomes affiliated with a different Community Banking Institution in the Restricted Area;

 

(b)    “become affiliated” shall mean, without limitation, engaging, participating, or being involved in any respect in the business of banking (other than as a depositor, borrower or other customer), or furnishing any aid, assistance or service of any kind to any person in connection with the business of the Company, the Bank and any of their affiliates, and shall include without limitation being employed by any Community Banking Institution which has a branch or other place of business in the Restricted Area; and

 

(c)    “Community Banking Institution” shall mean a bank with assets equal to or less than five billion dollars.

 

    	14

    	 

    
 

 

Nothing herein shall prohibit the Executive from purchasing or owning less than five percent (5%) of the securities or ownership interests of any corporation, partnership or limited liability company, provided that such ownership represents a passive investment and that the Executive is not a controlling person of, or a member of a group that controls, such corporation, partnership or limited liability company.

 

This Section 8 does not, in any way, restrict or impede the Executive from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order. The Executive shall promptly provide written notice of any such order to the Board of Directors.

 

8.3       Non-solicitation of Employees. The Executive agrees and covenants not to directly or indirectly solicit, hire, recruit, attempt to hire or recruit, or induce the termination of employment of any employee of the Company, the Bank or any of their Affiliates for the term of one (1) year, beginning on the last day of the Executive’s employment with the Company.

 

8.4       Non-solicitation of Clients. The Executive understands and acknowledges that because of the Executive’s experience with and relationship to the Company, he will have access to and learn about much or all of the clients, prospective clients and referral sources of the Company, the Bank and their affiliates. The Executive understands and acknowledges that loss of these client and referral relationships and/or goodwill will cause significant and irreparable harm. The Executive agrees and covenants, for a period of one (1) year, beginning on the last day of the Executive’s employment with the Company, not to directly or indirectly (a) solicit any actual or prospective client or client-referral source who had a business relationship with the Company, the Bank or any of their affiliates during the period of time in which the Executive was employed by the Company, it being expressly agreed that soliciting a referral from a prospective client or client-referral source is included within this prohibition; or (b) encourage any such client or client-referral source to turn down, terminate or reduce a business relationship with the Company, the Bank or any of their affiliates.

 

8.5       Non-disparagement. The Executive agrees and covenants that he will not at any time following the termination of his employment with the Company, make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company, the Bank, any of their affiliates or their respective businesses, or any of their employees, officers, and existing and prospective clients, except to the extent required by applicable law or regulation.

 

8.6       Non-Interference Covenant. For a period of one (1) year, beginning on the last day of the Executive’s employment with the Company, the Executive covenants and agrees that he will not, directly or indirectly and for whatever reason, whether for his own account or for the account of any other person, firm, corporation or other organization:

 

(a)      solicit, employ, or otherwise interfere with any of the contracts or relationships of the Company, the Bank or any of their affiliates with any employee, officer, director or any independent contractor who is employed by or associated with the Company, the Bank or any of their affiliates as of the Termination Date; or

 

    	15

    	 

    
 

 

(b)      actively solicit or cause to be solicited, or otherwise actively interfere with, any of the contracts or relationships of the Company, the Bank or any of their affiliates with any independent contractor, customer, client or supplier of the Company, the Bank or any of their affiliates.

 

8.7       Business Materials and Property Disclosure. All written materials, records, and documents made by the Executive or coming into his possession concerning the business or affairs of the Company, the Bank or any of their affiliates shall be the sole property of the Company. Upon termination of his employment with the Company, the Executive shall deliver the same to the Company and shall retain no copies, including but not limited to copies in paper, electronic, digital or any other format. The Executive shall also return to the Company all other property in his possession owned by the Company upon the termination of his employment.

 

If a court or arbitration panel concludes that the time period of the restriction set forth in this Section 8 is not enforceable or that a specific geographical scope must be stated herein, then the parties agree that such court or arbitration panel may rewrite the time period of this restriction and/or prescribe a geographical restriction to the maximum enforceable time period and geographical area permitted by law.

 

9.     Acknowledgement. The Executive acknowledges and agrees that the services to be rendered by his to the Company are of a special and unique character; that the Executive will obtain knowledge and skill relevant to the Company’s industry, methods of doing business and marketing strategies by virtue of the Executive’s employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable and reasonably necessary to protect the legitimate business interest of the Company.

 

The Executive further acknowledges that the amount of his compensation reflects, in part, his obligations and the Company’s rights under Section 7 and Section 8 of this Agreement; that he has no expectation of any additional compensation, royalties or other payment of any kind not otherwise referenced herein in connection herewith; and that he will not be subject to undue hardship by reason of his full compliance with the terms and conditions of Section 7 and Section 8 of this Agreement or the Company’s enforcement thereof.

 

10.   Remedies. In the event of a breach or threatened breach by the Executive of Section 7 or Section 8 of this Agreement, the Executive hereby consents and agrees that the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security. The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages or other available forms of relief.

 

    	16

    	 

    
 

 

11.   Arbitration. Any dispute whatsoever relating to the Executive’s employment by the Company, or any other dispute arising out of this Agreement which cannot be resolved by any party upon thirty (30) days’ written notice to the other party, shall be settled by binding arbitration at a mutually agreed location in Fairfield County, Connecticut in accordance with the then prevailing Employment Dispute Resolution Rules of the American Arbitration Association by a single arbitrator. The judgment upon the award rendered by the arbitrator may be entered in any court of competent jurisdiction. It is the purpose of this Agreement, and the intent of the parties hereto, to make the submission to arbitration of any dispute or controversy arising out of this Agreement, as set forth hereinabove, binding upon all parties hereto. This Section 11 shall not in any way restrict the right of the Company to obtain injunctive relief from a court of competent jurisdiction.

 

All arbitration costs and all other costs, including but not limited to reasonable attorneys’ fees, incurred by the Executive in an arbitration proceeding shall be paid by the Company in the event the Executive materially or substantively prevails in such arbitration proceeding. All arbitration costs and all other costs, including but not limited to reasonable attorneys’ fees, incurred by the Company in an arbitration proceeding shall be paid by the Executive in the event the Company materially or substantively prevails in such arbitration proceeding. As part of the judgment rendered by the arbitrator in an arbitration proceeding, the arbitrator shall determine which party (if any) has materially or substantively prevailed in such arbitration proceeding.

 

12.   Governing Law: Jurisdiction and Venue. This Agreement, for all purposes, shall be construed in accordance with the laws of Connecticut without regard to conflicts of law principles. Any action or proceeding by either of the parties to enforce this Agreement that is not covered by the Arbitration provision of Section 11 above shall be brought only in a state or federal court located in the state of Connecticut, county of Fairfield. The parties hereby irrevocably submit to the non-exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue.

 

13.   Source of Payments: No Duplication of Payments. All payments provided in this Agreement shall be timely paid in cash or check from the general funds of the Company or the Bank. Payments pursuant to this Agreement shall be allocated between the Company and the Bank in proportion to the approximate level of activity and the time expended on such activities by the Executive as determined by the Company and the Bank on a quarterly basis, unless the applicable provision of this Agreement specifies that the payment shall be made by either the Company or the Bank. In no event shall the Executive receive duplicate payments or benefits from the Company and the Bank.

 

14.   Entire Agreement. Unless specifically provided herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in court and can be cited as evidence in legal proceedings alleging breach of the Agreement.

 

15.   Modification and Waiver. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by the Chairman of the Board of Directors of the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.

 

    	17

    	 

    
 

 

16.    Severability. Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement.

 

The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law.

 

The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal or unenforceable provisions had not been set forth herein.

 

17.    Captions. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.

 

18.    Counterparts. This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.

 

19.    Tolling. Should the Executive violate any of the terms of the restrictive covenant obligations articulated herein, the time period for compliance with such obligations shall be tolled for the full period in which the Executive is in violation of such obligations, with the tolled period to be added to the period of time remaining following the first date on which the Executive ceases to be in violation of such obligation.

 

20.    Section 409A. This Agreement is intended to comply with Section 409A or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each instalment payment provided under this Agreement shall be treated as a separate payment. Notwithstanding any other provision of this Agreement, in the event any payment is to be made during a specified time period following the expiration of the Release Execution Period and the time period for such payment begins in one calendar year and ends in a second calendar year, then such amount shall be payable in the second calendar year. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Executive on account of non-compliance with Section 409A.

 

    	18

    	 

    
 

 

Notwithstanding any other provision of this Agreement, if any payment or benefit provided to the Executive in connection with his termination of employment is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and the Executive is determined to be a “specified employee” as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of the Termination Date (the “Specified Employee Payment Date”), unless the payment otherwise satisfies the short-term deferral exemption or another exemption under Section 409A of the Code. The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to the Executive in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule.

 

21.   Successors and Assigns. This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.

 

22.   Notice. Notices and all other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested, or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like notice):

 

	
If to the Company:

	 
	
Chairman

	
Compensation Committee

	
Bankwell Financial Group, Inc.

	
220 Elm Street

	
New Canaan, CT 06840

	  
	
If to the Executive:

	  
	
Christopher Gruseke

	
130 Rosebrook Road

	

New Canaan, CT 06840

 

    	19

    	 

    
 

 

23.   Representations of the Executive. The Executive represents and warrants to the Company that:

 

23.1    The Executive’s acceptance of employment with the Company and the performance his duties hereunder will not conflict with or result in a violation of, a breach of, or a default under any contract, agreement or understanding to which he is a party or is otherwise bound.

 

23.2    The Executive’s acceptance of employment with the Company and the performance of his duties hereunder will not violate any non-solicitation, non-competition or other similar covenant or agreement of a prior employer.

 

24.    Withholding. The Company shall have the right to withhold from any amount payable hereunder any federal, state and local taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation.

 

25.    Survival. Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.

 

26.    Acknowledgment of Full Understanding. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS AGREEMENT.

 

[SIGNATURE PAGE FOLLOWS]

 

    	20

    	 

    
 

 

IN WITNESS WHISEOF, the parties hereto have executed this Agreement as of the date first written above.

	 	 	  	  	  	  
	  	
BANKWELL FINANCIAL GROUP, INC.

	  	  
	  	
By

	/s/
James A. Fieber	  
	  	
Name: James A. Fieber

	  	
Title: Chairman of the Compensation

	  	
Committee

	  	  
	
EXECUTIVE

	  
	  	  
	

Signature:

	/s/ Christopher Gruseke	 	  
	  	  
	
Name: Christopher Gruseke

	  

 

 

    	21ex10-2.htm

Exhibit 10.2

 

 

Binding Term Sheet - Supply 

 

Confidential 

 

This binding term sheet (this “Binding Term Sheet”), dated as of October 15, 2014, is between Response Biomedical Corp., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (“Response”), and 杭州中翰盛泰生物技术有限公司, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Main Building, #519 Xingguo RD, Qianjiang Economic Development Zone, Hangzhou, Zhejiang Province, China (“JBT”) for supply by Response of raw materials for multiple Assays that will run on a New Analyzer developed by JBT. This Binding Term Sheet is intended to be a binding agreement between the parties until such time as the parties enter into Supply Agreement that more fully state the agreements between the parties with respect to the transactions described herein. 

 

Concurrently with this Binding Term Sheet, JBT and Response are entering into a Technology Development Agreement that is intended to lay the framework of the key terms for a Collaboration Agreement (defined below) between the Parties for co-development activities related to the materials to be supplied by Response to JBT under the Supply Agreement (the “Technology Development Agreement”). 

 

Concurrently with this Binding Term Sheet, Response is entering into a term sheet with each of HANGZHOU Joinstar Medical INSTRUMENT & REAGENT Co., Ltd. (“JMIR”) and Hangzhou Lizhu Medical Instrument & Reagent Co. (“HZLZ”) for JMIR and HZLZ to purchase Response common stock (the “Equity Purchases”).

 

The parties agree to use all reasonable efforts to complete negotiation and execution of the definitive Collaboration Agreement and the definitive Supply Agreement no later than three (3) months after execution of the Technology Development Agreement and this Binding Term Sheet. If the Collaboration Agreement or the Supply Agreement are not finalized and executed by the parties within such period, then Response may suspend activities under the Technology Development Agreement (and the timeline previously agreed by the parties shall be postponed accordingly). If the Collaboration Agreement or the Supply Agreement are not finalized and executed by the parties within six (6) months of execution of the Technology Development Agreement and this Binding Term Sheet, then the Technology Development Agreement and this Binding Term Sheet will terminate.

 

The parties agree to use all reasonable efforts to complete negotiation and execution of the definitive Equity Purchase Documents and transfer funds and close the equity purchase (“Equity Closing”) no later than three (3) months after execution of the Binding Term Sheet-Equity Investment (HZLZ) and Binding Term Sheet-Equity Investment (JMIR). If the Equity Closing has not occurred within such period, then Response may suspend activities under Technology Development Agreement (and the timeline previously agreed by the parties shall be postponed accordingly). If the Equity Closing has not occurred within six (6) months of execution of the Binding Term Sheet-Equity Investment (HZLZ) and Binding Term Sheet-Equity Investment (JMIR), then the Technology Development Agreement and this Binding Term Sheet, the Binding Term Sheet-Equity Investment (HZLZ) and the Binding Term Sheet-Equity Investment (JMIR), the definitive Collaboration Agreement (if executed) and the definitive Supply Agreement (if executed) will terminate; alternatively, if the Equity Closing cannot be accomplished within such period then the parties will meet to re-negotiate the financial terms of this Binding Term Sheet, the Technology Development Agreement, the definitive Collaboration Agreement (if executed) and the definitive Supply Agreement (if executed).

 

 

 

 

 

	
 

Definitions

	
 

1.
	
 

Assays: 
	
 

The assays for a particular biomarker to be co-developed under the Technology Development Agreement and/or the Collaboration Agreement by Response and JBT that will run on the New Analyzer.

	
 

2.
	
 

CDA: 
	
 

The Mutual Confidentiality Agreement between the parties, dated March 27, 2014. 

	
 

3.
	
 

CFDA:
	
 

China Food and Drug Administration. 

	
 

4.
	
 

Collaboration Agreement:
	
 

Agreement that contains terms for the co-development of Optics Block, Optics Software, and multiple Assays by Response and JBT that will run on the New Analyzer.

	
 

5.
	
 

Collaboration Markers:
	
 

The biomarker that is detected by an Assay that is agreed by both parties to be co-developed under the Technology Development Agreement and/or the Collaboration Agreement.

	
 

6.
	
 

Equity Purchase Documents:
	
 

The documents pursuant to which JMIR and HZLZ will purchase common shares of Response, as further described in the Binding Term Sheet-Equity Investment (JMIR) and Binding Term Sheet-Equity Investment (HZLZ).

	
 

7.
	
 

IPR:
	
 

Patents, trademarks, copyrights, trade secrets, know-how and other intellectual property rights. 

	
 

8.
	
 

Joint Development Committee or JDC:
	
 

Committee comprised of the project managers and additional members of each of JBT and Response as required that will meet regularly and oversee the development and other activities under this Binding Term Sheet, the Supply Agreement, the Technology Development Agreement and the Collaboration Agreement. 

	
 

9.
	
 

Joint Steering Committee or JSC:
	
 

Committee comprised of one senior executive of each of JBT and Response and up to 2 other members of each of JBT and Response that will meet regularly and oversee all of the parties’ activities under this Binding Term Sheet, the Supply Agreement, the Technology Development Agreement and the Collaboration Agreement.

	
 

10.
	
 

New Analyzer:
	
 

The Immunoassay analyzer for rapid test purposes developed by JBT that has all of the following four characteristics: (a) [***]1, (b) [***], (c) [***], and (d) [***]. 

 

 

-2-

 

 

	
 

11.
	
 

Optics Block:
	
 

[***].

	
 

12.
	
 

Optics Software:
	
 

[***].

	
 

13.
	
 

Software for Calibration Curve Generation:
	
 

[***].

	
 

14.
	
 

Raw Materials
	
 

Means raw materials for use in manufacturing Assays, with details to be confirmed by the Parties through the JDC.

	
 

15.
	
 

Supply Agreement: 
	
 

Agreement that contains terms for the supply of Raw Materials for multiple Assays by Response that will run on a New Analyzer developed by JBT.

	
 

Intellectual Property Rights:

	
 

16.
	
 

Third Party Rights: 
	
 

i.    Each party will be responsible for any infringement by it of any third party IPRs during the performance of its obligations under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement. In addition, each party shall indemnify, defend, hold the other party harmless from and against claims or suits arising during the term of the Technology Development Agreement and/or Collaboration Agreement and/or the Supply Agreement from infringement of third party IPRs as a result of use of IPR provided to such other party by or on behalf of the providing party, where such use is within the scope of the rights granted and the infringement would not have arisen but for such use.

 

ii.   The total amount payable under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement contains all fees (a) which result from infringement of any third party rights within China and other agreed territories and is Response’s responsibility; and (b) for any third party IPR which should be used or possibly be used later for purposes of the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement within China and other agreed territories and is Response’s responsibility, and JBT will not pay extra fees. Response will not be responsible for any infringement outside of China or such other agreed territories.

 

1 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-3-

 

 

	
 

17.
	
 

IPR: 
	
 

17.1   Each of JBT and Response will own all IPR respectively that was owned by such party as of the date of execution of the Technology Development Agreement and is thereafter developed by such party independent of the activities under the Technology Development Agreement, the Collaboration Agreement and the Supply Agreement (with respect to each party, the “Background IPR”). Nothing in the Technology Development Agreement, the Collaboration Agreement or the Supply Agreement will be deemed to transfer ownership of any Background IPR of a party, or, except as expressly set forth below, any other IPR owned or controlled by a party.

 

17.2  As a consideration to Sections 17.3 & 17.4 herein, IPR that arises from the activities under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement that relates to the development, transfer and/or manufacture of [***]2 will be owned solely by Response. Response agrees to provide a license for such IPR free of charge to use on the New Analyzer developed by JBT. After the Supply Agreement expires, Response agrees to continue to provide a license for such IPR free of charge to use on New Analyzer already manufactured or installed by JBT.

 

17.3  As a consideration to Section 17.2, IPR of [***] arising under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement, which is [***], will be owned solely by JBT. The term [***] means that [***]. 

 

For the avoidance of doubt, this excludes Background IPR of Response and IPR of [***]that is [***]  (“[***]”). To the extent JBT uses the “[***] “in the New Analyzer, during the term of the Technology DevelopmentAgreement, the Collaboration Agreement, the Supply Agreement and thereafter, Response agrees to grant a license for such IPR with respect to [***]for free.

 

17.4  As a consideration to Section 17.2, unless otherwise agreed by Response and JBT, IPR that arises from the activities of JBT and/or Response under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement that relates to the New Analyzer (other than [***]) will be owned solely by JBT.

 

2 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-4-

 

 

	 	 	
 

17.5  Except as set forth in Sections 17.2, 17.3, and17.4 above, each of JBT and Response will own all IPR respectively that arises from such party’s activities under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement and is not jointly invented with the other party.

 

17.6  Except as set forth in Sections 17.2, 17.3, 17.4 and17.5 above, Response and JBT agrees, as for IPR for new Collaboration Markers and IPR that arise from such party’s activities under the Technology Development Agreement, the Collaboration Agreement and/or the Supply Agreement and is jointly invented , both parties will negotiate in good faith about the percentage of the joint ownership or rights for commercialization in various jurisdictions. 

 

17.7  Each of JBT and Response will execute all documents and take other action as reasonably requested by the other party to give effect to the ownership of IPR as set forth above.

 

17.8  IPR owned by a party will be considered to be Confidential Information (as defined in the CDA) of such party pursuant to the CDA; provided, however, that such IPR will no longer be considered Confidential Information to the extent disclosed in a published patent application. 

 

17.9  Response pledges that JBT’s right of using relative IPRs granted by and in accordance with the Technology Development Agreement as well as Collaboration Agreement will not be restricted, interfered or diminished by reasons of the alteration of the owner(s) or user(s) of these relative IPRs.

 

17.10  Response and JBT pledge that right of using IPR which is jointly invented under 17.6 will not be restricted, interfered or diminished by reasons of the alteration of the owner(s) or user(s) of these relative IPRs.

	
 

18.
	
 

Technology Escrow:
	
 

Upon completion of the development phase of the definitive Collaboration Agreement, JBT and Response will arrange for escrow of manufacturing instructions and other know-how sufficient to instruct JBT how to manufacture Raw Materials. The escrow materials will be released from escrow solely to JBT free of charge, whilst JBT will obtain a royalty free, ongoing license, if Response declares bankruptcy or makes a general assignment for the benefit of its creditors, or if JBT terminates the Collaboration Agreement or the Supply Agreement due to uncured unilateral material breach by Response (following notice and opportunity to cure pursuant to the termination provisions of the applicable agreement).

 

 

-5-

 

 

	
 

Other Provisions 

	
 

19.
	
 

Project Team: 
	
 

i.            Response and JBT will use reasonable efforts to keep the same project team working on the development activities under the Technology Development Agreement, the Collaboration Agreement and the Supply Agreement. 

 

ii.           Response and JBT will each provide the other a project team list, including each member’s role. 

 

iii.          Response and JBT will ensure that each of their employee’s on the project team has signed an agreement containing provisions protecting the confidentiality of the employing party’s proprietary information and proprietary information belonging to third parties that is received by the employing party, and with the obligations of confidentiality under such agreement surviving until five (5) years after such person is no longer employed by the employing party.

	
 

20.
	
 

Non-Compete: 
	
 

20.1       During the term of the Technology Development Agreement, the Collaboration Agreement and the Supply Agreement, Response will not develop on its own or assist any other company or individuals to develop or use an Immunoassay analyzer stated in this Section 20.1. “Immunoassay analyzer stated in this Section 20.1” means an analyzer which meets both of the following two characteristics: 

●   Will [***]3, and 

●   Has all of the following four characteristics: (a) [***], (b[***], (c) [***], and (d) [***] 

 

20.2 Response will not (A) develop tests that detect Collaboration Markers, or Raw Materials or reagents for use in manufacturing tests that detect Collaboration Markers, for any other third party, or (B) supply, donate or otherwise transfer such Collaboration Markers, Raw Materials and reagents to any other third party, in case of each of (A) and (B), for an Immunoassay analyzer described in Section 20.1 above.

 

3 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 

-6-

 

 

	 	 	
 

20.3 During the term of the Technology Development Agreement, the Collaboration Agreement and the Supply Agreement, within China and other agreed marketing territory, for tests for the New Analyzer that detect Collaboration Markers, JBT will only market the Assays which it collaborates with Response on the New Analyzer; JBT will not sell or use tests for the New Analyzer which detect biomarkers that are the same as Collaboration Markers. As for other biomarkers beyond the parties’ collaboration, JBT has rights to choose freely.

 

20.4 When JBT intends to market outside China and any other agreed marketing territory, tests for the same biomarkers as the Collaboration Markers for the New Analyzer, JBT shall notify Response 15 months in advance. After following the procedure in this paragraph with respect to a given territory, JBT will have the rights to market in such territory its self-developed assay kits having biomarkers of the same kind as the Collaboration Markers if Response fails to agree for JBT to market in such territory within 4 months of receiving written notice. JBT shall notify Response of no more than 5 territories on a monthly basis, unless agreed by Response and JBT.

 

20.5  If one party has desires to perform activities that are contrary to Section 20.1, 20.2, or 20.3, it will carry out such activities only with the other party’s written consent, such written consent not to be unreasonably withheld, delayed or conditioned.

	
 

Supply

	
 

21.
	
 

Supply: 
	
 

Response will supply Raw Materials to JBT pursuant to the definitive Supply Agreement. 

 

The JSC will meet and establish detailed responsibilities and obligations of each Party under the Supply Agreement, as well as the requirements and specifications for the Raw Materials. The JSC may also agree that Response will supply other materials to JBT under the Supply Agreement. The JSC may agree to amend the detailed responsibilities and obligations of each Party from time-to-time.

	
 

22.
	
 

Restrictions: 
	
 

i.    JBT will use the Raw Materials solely within China to manufacture finished Assays for use in the New Analyzer. 

 

ii.   JBT will not subcontract such manufacturing activities to any third party without Response’s prior written consent. 

 

iii.  JBT will have no rights to resell Raw Materials or semi-products or any component thereof, other than finished Assays for use in the New Analyzer. 

 

 

-7-

 

 

	 	 	
 

iv.     JBT will not sell Assays outside of China or other agreed territories (and will not allow any of its distributors, resellers or other agents to do so) without first following the process outlined in Section 20.4 above.

	
 

23.
	
 

Term and Termination: 
	
 

i.      With respect to each Assay, the initial term of the Supply Agreement will commence on the date the agreement is executed and end 5 years after such Assay receives CFDA approval (the “Assay Initial Term”). With respect to each Assay, the term will automatically renew for an additional 5 years (the “Assay Renewal Term”, and together with the Assay Initial Term, the “Assay Supply Term”). 

 

ii.     With respect to each Assay, following the Assay Renewal Term the Assay Supply Term will automatically renew for additional successive one year periods upon expiration of the applicable Assay Supply Term unless either JBT or Response gives written notice of termination of the applicable Assay Supply Term at least 90 days prior to expiration of the then-current term. 

 

iii.    The Supply Agreement will terminate in its entirety upon expiration or termination of all Assay Supply Terms. 

 

	 	 	
iv.    The Supply Agreement will also terminate upon early termination of the Collaboration Agreement. 

 

v.      Either party has the right to unilaterally terminate this Binding Term Sheet and the Supply Agreement if the other party does not cure its material breach within 30 days of receipt of written notice of the material breach from the notifying party. Termination in accordance with this paragraph will take effect when the notifying party which claims to terminate this Binding Term Sheet or the Supply Agreement sends written notice of termination after expiration of the 30-day cure period.

 

vi.     Material breach: Material breach and cure mechanics will be further defined in the definitive Supply Agreement and specific provisions of the agreement will be referenced in this definition, which may include breach of Sections 16, 17, 19(iii), 20, 23(vi), 31 and/or 34 and/or other material breach of the Supply Agreement.

 

vii.   The Collaboration Agreement will terminate upon expiration or termination of the Supply Agreement.

 

 

-8-

 

 

	 	 	 
	
 

24.
	
 

Transfer Prices:
	
 

i.      The transfer prices for Raw Materials for each Assay (“Transfer Price”) for the applicable Assay Initial Term will be as follows: 

	 	 	 	 		 
	
 
	
 
	
 

        * Transfer Prices are as FCA (Incoterms 2010), Vancouver, and do not include shipping costs or taxes, duties under China law and other China governmental charges.

        *The Transfer Price does include any royalty payable by Response to its licensors. The Transfer Price for Assay #1 should be minus [***]USD/Test when Response stops paying royalty

 

ii.     The Transfer Prices set forth above are based on JBT meeting the Estimated Minimum Purchase Amount for all 5 Assays for the first 5 years’ of the supply term as set forth on SCHEDULE A to this Binding Term Sheet (“Estimated Minimum Purchase Amount”). 

 

iii.    JBT will confirm next year’s Estimated Minimum Purchase Amount by December of every year, for all 5 Assays. If the Estimated Minimum Purchase Amount is not met 2 years in a row, JBT and Response will meet and agree in good faith on an increased Transfer Price for such Assays on commercially reasonable terms to adequately compensate Response for the shortfall in volume.

 

iv.    How to calculate amount for Raw Materials of Assay when Response invoices to JBT: JBT and Response will finalize how to calculate quantities, scrap rate or wastage rate (through the JSC).

	
 

25.

 
	
 

Post Assay Initial Term Pricing: 
	
 

If Response or JBT wants to change the Transfer Price for Raw Materials after the Assay Initial Term (other than as set forth in the Transfer Price section above), Response may request an increase in Transfer Price for a particular item only if the material and labor costs for such item have increased since the time the price was last set, whilst JBT may request a decrease in Transfer Prices for a particular item only if its average ex-factory selling price (i.e., JBT’s selling price including VAT, but excluding other taxes and shipping and handling fees) for such item is below the agreed sales price specified in Section 29 below, such party which claims to such activities will notify other party to negotiate 18 months in advance, after which notice JBT and Response will negotiate in good faith to reach a consensus, if not agreed, execute as per latest set Transfer Price. 

 

4 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-9-

 

 

	
 

26.
	
 

Supply Payment Terms and Lead Times:
	
 

i.     JBT will pay for Raw Materials as follows: after prepayment of [***]5 of order amount, Response should ship within 5 business days as per order, remaining [***]costs will be paid within [***] days after the order is picked up from Vancouver.

 

ii.    Lead times: The Supply Agreement will set forth the maximum time between the receipt of an order by Response from JBT and the order departure from Vancouver, and will be determined further.

 

iii.   Response will invoice to JBT timely.
	 
	
 

27.
	
 

QC Acceptance Testing:
	
 

QC acceptance: JBT and Response will establish the QC acceptance criteria through the JDC, and such QC acceptance criteria shall be finalized prior to the shipment of the first batch of product under the Supply Agreement; when the Raw Materials, Optics Block, Finished Component Test Materials and other products arrive at JBT, they will be inspected in accordance with the agreed acceptance criteria. 
	 
	
 

28.
	
 

Forecasting: 
	
 

JBT will confirm next year’s expected purchase amount by Assay, as well as the Estimated Minimum Purchase Amount, by December of every year. JBT will provide Response with monthly rolling forecasts 12 months in advance. The first 6 months of such forecasts will be binding on JBT. 
	 
	
 

29.
	
 

Revenue Sharing:
	
 

Definition for “Revenue Sharing”: For Assays which are manufactured by JBT with Raw Materials supplied by RBM and then used on New Analyzer, the sales amount is calculated based on the “Agreed Pricing” (which includes VAT, but excludes other taxes and shipping and handling fees) in the table below and the actual sales quantity of tests, then amounts will be payable to Response as per Revenue Sharing Percentage in this clause.
	 

 

5 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-10-

 

 

	
 
	
 
	
 

 

 

 

Revenue Sharing will be implemented as follows:

 

i.         For the Assay Initial Term: Subject to the Revenue Sharing Cap per Assay (see Section 30):

 

 

ii.        For the Assay Renewal Term: 

 

 

iii.       For any successive renewal term the Revenue Sharing Percentage will be [***]% 
	 

 

6 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

7 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-11-

 

 

	
 

30.
	
 

Revenue Sharing Cap and Credits:
	
 

i.     For Revenue Sharing payable during the Assay Initial Terms, Revenue Sharing will be capped at an aggregate of $3.1 Million USD total for all Assay Initial Terms with the maximum allocated on a per Assay basis based on the following schedule (“Revenue Sharing Cap per Assay”):

 

 

 

 

 

ii.     If at the end of the Assay Initial Term for a given Assay, JBT has not paid Response the full amount of the “Revenue Sharing Cap per Assay After Deducting Revenue Sharing Credit of such Assay”, then, within 30 days after the end of the applicable Assay Initial Term, JBT will pay Response the difference between the actual Revenue Sharing paid for such Assay and the “Revenue Sharing Cap per Assay After Deducting Revenue Sharing Credit of such Assay”.

 

iii.   JBT will receive a credit against Revenue Sharing payments for each Assay as set forth in the table above with respect to each Assay, the “Revenue Sharing Credit per Assay”). JBT will not be required to make Revenue Sharing payments for a particular Assay until the Revenue Sharing Credit per Assay for such Assay is exhausted.

	
 

31.
	
 

Revenue Sharing Reporting and Payment:
	
 

i.      JBT will calculate Revenue Sharing on a calendar half year basis (namely Jan-June, July-Dec). Within 35 days after the end of each calendar half year, JBT will submit to Response a report detailing the Revenue Sharing calculation on a per Assay basis, Response will confirm such report within 5 business days after receiving such report. JBT will pay the applicable Revenue Sharing Amount within 5 business days based on agreed reports.

 

8 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-12-

 

 

	
 
	
 
	
 

ii.    The parties will discuss further the possibility of addressing Revenue Sharing payment as payments for technical services, or by adjusting the Transfer Price to include the relevant amounts or by such other means as agreed by Parties.

 

iii.   Response will have rights to confirm sales quantities which are provided by JBT.

 

	
 

32.
	
 

Tax 税:
	
 

The amounts set forth above are inclusive of China taxes (Withholding of China taxes (if any) will be the responsibility of JBT, but JBT will pay the remaining amounts to Response after JBT fulfills any withholding duty from amounts payable to Response for Revenue Sharing under this Binding Term Sheet) under China law. JBT will provide a tax receipt if requested by Response.) Response will also be responsible at its own expense for taxes or charges under Canada law.

	
 

General Provisions. 

	
 

33.
	
 

Payments: 
	
 

All payments under this Binding Term Sheet and the definitive Supply Agreement will be made in U.S. Dollars.

	
 

34.
	
 

Assignment Rights: 
	
 

Neither party will have the right to assign any or all of its rights and obligations under this Binding Term Sheet or the Supply Agreement without first obtaining the written consent of the other party.  

	
 

35.
	
 

Confidentiality: 
	
 

The terms of the CDA will apply to the parties’ activities under this Binding Term Sheet. This Binding Term Sheet will be considered confidential information of each party and will be subject to the terms of the CDA. Except as set forth below, or as may be required by law (including applicable securities laws), no information regarding this Binding Term Sheet will be made public without the prior written consent of the other party. 

	
 

36.
	
 

Press Releases: 
	
 

Notwithstanding the foregoing, each party will have the right to issue press releases and other public disclosures regarding this Binding Term Sheet and/or the Supply Agreement (and the related activities of the parties) if required by applicable securities law. 

 

The issuing party will provide the other party with a draft of any proposed press release related to this Binding Term Sheet and/or the Supply Agreement before any public release. The issuing party will use reasonable efforts to provide 24 hours for review of the press release and will reasonably consider any comments received from the other party, subject to the issuing party’s legal obligations for disclosure.

Any other press releases or public disclosures regarding this Binding Term Sheet and/or the Supply Agreement (and the related activities of the parties), will only be made if agreed by both of the parties. 

 

 

-13-

 

 

	
 

37.
	
 

Governing Law: 
	
 

This Binding Term Sheet and the Supply Agreement and the rights of the parties hereunder shall be governed by and interpreted in accordance with the laws of People’s Republic of China. 

	
 

38.
	
 

Settlement of Disputes: 
	
 

In the event of a dispute arising out of or in connection with this Binding Term Sheet or the Supply Agreement, or in respect of any legal relationship associated with it or from it, which does not involve a party seeking a court injunction or other injunctive or equitable relief to protect its business, confidential information or intellectual property, that dispute will be resolved confidentially as follows: 

 

i.     Amicable Negotiation – The parties agree that, both during and after the performance of their responsibilities under this Binding Term Sheet or the Supply Agreement, each of them will make bona fide efforts to resolve any disputes arising between them by amicable negotiations; and

ii.    Arbitration – If the parties have been unable to resolve a dispute within 30 days or such other period agreed to in writing by the parties, after the negotiation begins, then any party may make application to the China International Economic and Trade Arbitration Commission or CIETAC to solve the dispute by arbitration. The arbitration will be held in Beijing, China in accordance with the rules of CIETAC then in effect. The Arbitration award shall be final and binding on the parties and may be enforced in any court of competent jurisdiction.

	
 

39.
	
 

Survival: 
	
 

Sections 16, 17, 19(iii), 34, 35, 37, 38, 39, 40 and 41 will survive expiration or termination of this Binding Term Sheet. 

	
 

40.
	
 

Counterparts: 
	
 

This Binding Term Sheet and the Supply Agreement may be executed in counterparts or duplicate originals, all of which are regarded as one and the same instrument. The parties consent to use of facsimile, electronic and/or digital signatures in the execution of this Binding Term Sheet and the Supply Agreement, and the same are binding upon the parties as if they were original signatures. Facsimile, electronic and digital copies of this Binding Term Sheet and the Supply Agreement, including properly executed PDF versions of this Binding Term Sheet and the Supply Agreement, are regarded as original instruments by the parties.

	
 

41.
	
 

Languages 
	
 

This Binding Term Sheet and the Supply Agreement will be written in English and Chinese. English and Chinese versions shall have the same legal force Should there be any inconsistency or conflict between the Chinese and English language versions, the principle enunciated in the second paragraph of Article 125 of the current PRC Contract Law shall apply.

 

 

-14-

 

 

Agreed to this 15th day of October, 2014:

 

 

 

	Response Biomedical Corp.	 	HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD
	 	 	 
	By:	/s/ William Adams	 	By:	/s/ Xuyi Zhou
	 	 	 	 	 
	Name:	William Adams	 	Name:	Xuyi Zhou
	 	 	 	 	 
	Title:	Chief Financial Officer	 	Title:	General Manager

 

 

-15-

 

 

SCHEDULE A 

 

Estimated Minimum Purchase Amount (units)

 

	
Assay
	
First Year after CFDA registration 
	
Second Year
	
Third Year
	
Fourth Year
	
Fifth Year
	
sales quantity for 5 years

	
Assay #1
	
[***]9
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Assay #2
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Assay #3
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Assay #4
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Assay #5
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Estimated Minimum Purchase Amount
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

 

*JBT confirm next year’s Estimated Minimum Purchase Amount by December of every year.

 

 

	
Assay
	
Marker

	
Assay #1
	
[***]9

	
Assay #2
	
[***]

	
Assay #3
	
[***]

	
Assay #4
	
[***]

	
Assay #5
	
[***]

 

9 [***] Certain information has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

-16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]